Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF.
rivastigmine capsule and patch with concurrent Vascular risk factors (VRF)
rivastigmine capsule and patch without concurrent Vascular risk factors (VRF)
incidence of adverse events